VNDA - Total Utang marang Modal Vanda

Vanda Pharmaceuticals (VNDA) operates within an autonomous production cycle, rendering the company a resilient defensive asset regardless of global market conditions. An efficient delivery system for specialized drugs via various operators ensures uninterrupted supply and high profitability. This chart of the total debt-to-equity ratio stands at 0.09. The business relies on the development of unique therapies for severe sleep disorders and schizophrenia.

VNDA: Total Utang marang Modal Vanda Pharmaceuticals Inc. 04.07.2022 - 30.10.2026

Rincian analitis perusahaan Vanda Pharmaceuticals

- rega lan prakiraan konsensus rega:

Bagan rega Vanda Pharmaceuticals Inc.|VNDA - Bagan tingkat prakiraan

- statistik kapitalisasi pasar:

Kapitalisasi pasar Vanda Pharmaceuticals|VNDA - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Nilai Buku saben Saham Vanda Pharmaceuticals|VNDA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku vandapharma.com|VNDA - Nilai Agregat Aset

- indikator total utang lan likuiditas perusahaan:

Utang marang Ekuitas Vanda Pharmaceuticals|VNDA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Vanda Pharmaceuticals|VNDA - Gunggung utang perusahaan|Utang marang nilai buku Vanda Pharmaceuticals|VNDA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Vanda Pharmaceuticals|Likuiditas cepet vandapharma.com

- informasi bathi lan kelipatan valuasi:

VNDA - Asil keuangan resik

Analisis dhasar perusahaan:Vanda Pharmaceuticals Inc.

This ratio determines financial stability through the balance of borrowed and equity funds. It measures the degree of business dependence on external financing, identifying risks of cash flow gaps. Analyzing the company's debt-to-equity ratio allows for an assessment of asset protection against bankruptcy. For Vanda Pharmaceuticals (VNDA), this leverage is critical due to patent litigation. A stable level of indebtedness offsets the brand's legal volatility.

Analisis pesaing Vanda Pharmaceuticals

Utang marang Ekuitas Alkermes|Avadel Pharmaceuticals PLC - Utang Agregat marang Ekuitas|Total Utang marang Modal ATAI|GHRS (GH Research Group) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MNMD (Mind Medicine)|Total Utang marang Modal compasspathways.com CMPS|LBRX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi DRUG (Bright Minds Bio)|cybin.com (CYBN) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Alto Neuroscience Corp|NRXP (NRx Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal Cingulate Corp|Rasio Total Utang marang Ekuitas SILO (Silo Pharma, Inc.)|CPHI (chinapharmaholdings.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Clearmind Medicine CMND|PBM (Psyence Bio) - Utang Agregat marang Ekuitas|SPRC - Utang marang Ekuitas|Koefisien Total Utang marang Modal seelostherapeutics.com SEEL|VRPX (virpaxpharma.com) - Rasio Total Utang marang Ekuitas|Utang marang Modal Karuna Therapeutics Inc (KRTX)